So why did the first pyrilutamide phase III fail? Research/Science 8/7/2026
Similar Community Posts Join
5 / 1000+ resultscommunity Kintor has released an investor relations memo regarding Chinese Phase III trials for Pyrilutamide
Kintor's Pyrilutamide (KX-826) showed hair growth in Chinese Phase III trials but did not significantly outperform placebo. The treatment was safe with no major adverse reactions reported.
community Kintor Phase 2 Results released KX-826 (pyrilutamide)
Kintor Pharmaceutical's Phase 2 results with the drug Pyrilutamide, a potential alternative to 5-ARI drugs like Finasteride and Dutasteride but without the side effects. It could be used in combination with other topical treatments such as Minoxidil. The safety of the drug has been demonstrated in 6 months of use, however there are still questions about long term efficacy and systemic absorption.
community Pyrilutamide Phase 3 on its way
Pyrilutamide Phase 3 approved, starting early 2022 with 416 subjects for 24 weeks. Drug potentially better than RU and Breezula, with some users reporting no side effects.
community GT20029 China Phase II Trial For AGA Reached Primary Endpoint
The GT20029 tincture, a topical androgen receptor degrader, showed significant hair growth and good safety in a China Phase II trial for male androgenetic alopecia (AGA), with the 1% dose twice weekly identified as optimal. The company plans to initiate Phase III trials in China and Phase II in the U.S., and the treatment also shows promise for acne.
community Why do I have the feeling that this subreddit is flooded by Kintor employees?
Users discuss aggressive promotion of Koshine 826, suspecting Kintor employees are behind it. Concerns are raised about its effectiveness, with some preferring alternatives like finasteride and minoxidil.
Related Research
6 / 1000+ resultsresearch Mechanism exploration of the combined use of minoxidil with natural compounds ginsenoside Rg3 and glycyrrhizic acid for enhancing androgenic alopecia therapy
Combining minoxidil with ginsenoside Rg3 and glycyrrhizic acid offers a more effective treatment for androgenic alopecia.
research Molecular Mechanisms and Targeted Therapeutics in Androgenetic Alopecia: From Signaling Pathways to Regenerative Approaches
Future treatments for hair loss may focus on personalized and regenerative approaches.
research The Frontal Fibrosing Alopecia Syndrome: How a Single Word Name Change Might Change So Much
Renaming frontal fibrosing alopecia to a syndrome could improve diagnosis and treatment.
research Total Synthesis of Calanthoside, a Potential Hair Growth Stimulant: A Facile Synthetic Approach via One-Pot S- and O-Glucosidic Bond Formation
Calanthoside, a potential hair growth stimulant, was successfully synthesized using a new, efficient method.
research Comparison of Pain Levels in Anterior Versus Cephalic Approach for Supraorbital/Supratrochlear Nerve Blocks
The cephalic approach for nerve blocks is less painful than the anterior approach during hair restoration surgery.
research Brain allopregnanolone induces marked scratching behaviour in diet-induced atopic dermatitis mouse model
A brain-produced steroid causes increased scratching in mice with a skin condition similar to eczema.